Zhi Tong Cai Jing·2026-01-07 07:10Core Viewpoint - Rongchang Biopharma (09995) experienced a significant stock increase of over 11%, reaching HKD 90.15 with a trading volume of HKD 577 million, following the announcement of promising clinical trial data for its PD-1/VEGF bispecific antibody RC148 in treating non-small cell lung cancer [1] Group 1: Clinical Research and Drug Development - The clinical research data for RC148, both as a monotherapy and in combination therapy, demonstrated outstanding clinical efficacy and manageable safety, achieving a dual-pathway breakthrough [1] - Rongchang Biopharma's two innovative drugs have successfully been included in the 2025 National Medical Insurance Drug List for four indications [1] Group 2: Commercialization and Market Position - According to Zhongtai Securities, Rongchang Biopharma is accelerating its commercialization capabilities and is rapidly approaching the breakeven point through efficient operations and targeted investments [1] - The company’s drug, Vidisicimab, is proposed to be included as a breakthrough therapy for a new indication, in combination with trastuzumab and toripalimab for first-line treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma, which would mark its fourth breakthrough therapy designation if approved [1]